Navigation Links
Kite Pharma Appoints Cynthia M. Butitta as Chief Financial Officer

LOS ANGELES, Jan. 8, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Cynthia M. Butitta to the newly created position of Executive Vice President and Chief Financial Officer.  A veteran financial and operational executive, Ms. Butitta brings over 20 years' experience in leadership roles in the biotech and technology industries.  Her appointment is effective immediately.


Arie Belldegrun, M.D., Founder and Executive Chairman of the Board of Kite Pharma, commented, "Cindy has an outstanding track record and depth and breadth of experience in capital fund raising, strategic planning and investor relations at both private and public biotechnology companies.  We are delighted to welcome her to the team and believe her unique capabilities and expertise will greatly benefit Kite as we pursue our clinical and business objectives."

Prior to joining Kite, Ms. Butitta served as Senior Vice President, Chief Financial Officer of NextWave Pharmaceuticals.  During her tenure, Ms. Butitta was responsible for finance and administration, distribution and project management and played a key role in the Company's acquisition by Pfizer, Inc. for $700 million.  Previously, she was Chief Financial Officer and Chief Operating Officer of Telik, Inc.  At Telik, Ms. Butitta was responsible for securing over $450 million through an IPO and subsequent follow-on offerings and oversaw financial reporting and controls, investor relations, information technology, manufacturing, quality, project management and commercial operations.  Previously, she served as Vice President of Finance and Administration and Chief Financial Officer for Connetics, Inc., a public biotechnology company.  Ms. Butitta received her B.S. degree with honors in Business and Accounting from Edgewood College in Madison, Wisconsin and her MBA degree in Finance from the University of Wisconsin, Madison.

Ms. Butitta stated, "I am thrilled to join the accomplished executive management team at Kite.  As a leading company in the emerging and highly promising field of immunotherapy, Kite has the opportunity to play a pivotal role in changing the way we approach cancer.  It is an exciting time for the Company, with recent clinical breakthroughs reported at a major cancer conference, and I look forward to contributing to Kite's continued evolution and growing presence within the life sciences industry."

About Kite Pharma

Kite Pharma, Inc. (Kite) is a privately held development stage biotechnology company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch, Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR and TCR products, directed to a wide range of cancer indications. These novel personalized and targeted immunotherapies, which capitalize on the selectivity and potency of immune cells, are designed to provide significant and durable clinical benefit regardless of tumor origin, disease stage, and prior treatments. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing cutting-edge immunotherapies and oncology treatments. Kite is based in Los Angeles, CA.  For more information, visit the company's website at

Kite Contact:
Dr. Arie Belldegrun
Executive Chairman

For Media:
Justin Jackson
Burns McClellan
(212) 213-0006

SOURCE Kite Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
2. Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference
3. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
4. Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma
5. Kite Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference
6. Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates - Research Report on NPS Pharmaceuticals, Oramed, PAREXEL, PhotoMedex, and Cell Therapeutics
7. Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
8. Velocity Pharmaceutical Development Announces Appointment of Stuart Sedlack as Senior Vice President, Business Development
9. Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 13
10. Ralphs Pharmacies Providing Prescriptions at No Upfront Cost for Customers Enrolled in the Public Health Insurance Marketplace
11. CVS/pharmacy Helps Customers Kick Off a Healthy New Year with Online Vitamin Resources and Huge Savings
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
Breaking Medicine News(10 mins):